公开(公告)号：US10179773B2

公开(公告)日：2019-01-15

申请号：US15510589

申请日：2015-09-09

Applicant: EPIZYME, INC.

Inventor： Richard Chesworth ,  Megan Alene Cloonan Foley ,  Kevin Wayne Kuntz ,  Lorna Helen Mitchell ,  Jennifer C. Petter ,  Carl Eric Schwartz

IPC: A61P35/00 ,  A61P35/02 ,  A61P35/04 ,  C07D261/18 ,  C07D413/12

Abstract: The present disclosure provides substituted isoxazole carboxamides having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, X, n, and m are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.

公开(公告)号：US10669243B2

公开(公告)日：2020-06-02

申请号：US16245986

申请日：2019-01-11

Applicant: EPIZYME, INC.

Inventor： Richard Chesworth ,  Megan Alene Cloonan Foley ,  Kevin Wayne Kuntz ,  Lorna Helen Mitchell ,  Jennifer C. Petter ,  Carl Eric Schwartz

IPC: C07D261/18 ,  C07D413/12 ,  A61P35/02 ,  A61P35/04 ,  A61P35/00

Abstract: The present disclosure provides provides substituted isoxazole carboxamides having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, X, n, and m are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.

公开(公告)号：US20190241529A1

公开(公告)日：2019-08-08

申请号：US16245986

申请日：2019-01-11

Applicant: EPIZYME, INC.

Inventor： Richard Chesworth ,  Megan Alene Cloonan Foley ,  Kevin Wayne Kuntz ,  Lorna Helen Mitchell ,  Jennifer C. Petter ,  Carl Eric Schwartz

IPC: C07D261/18 ,  A61P35/00 ,  C07D413/12 ,  A61P35/02 ,  A61P35/04

Abstract: The present disclosure provides provides substituted isoxazole carboxamides having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, X, n, and m are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.